Trial site
Kansas City
Kansas City, Missouri 64111, United StatesNot linked to an institution yet
- 11running trials
- 8closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 25 trials
- Phase 12 trials
- Phase 1/22 trials
- Status
- Completed8 trials
- Recruiting6 trials
- Active, not recruiting5 trials
- Lead sponsor
- GlaxoSmithKline10 trials
- ViiV Healthcare7 trials
- Tesaro, Inc.2 trials
Running trials
Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707· Phase 3· GlaxoSmithKline· Source
Contact: Srinivas Nalamachu (principal investigator)
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Contact: Blair Thedinger (principal investigator)
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Contact: Craig Dietz (principal investigator)
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227· Phase 3· GlaxoSmithKline· Source
Contact: Paresh Patel (principal investigator)
Active, not recruiting
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384· Phase 1· ViiV Healthcare· Source
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043· Phase 2· GlaxoSmithKline· Source
Contact: Bradley Freilich (principal investigator)
Active, not recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397· Phase 2· ViiV Healthcare· Source
Active, not recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· Phase 3· ViiV Healthcare· Source
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323· Phase 3· GlaxoSmithKline· Source
Contact: Mario Castro (principal investigator)
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error